FDA Approves Novel RAS-Targeted Drug for Advanced Pancreatic Cancer
The FDA has granted expedited approval to daraxonrasib (Rasonque), the first RAS inhibitor for metastatic pancreatic adenocarcinoma. This pill targets a mutated protein in over 90% of cases and nearly doubled survival time in trials, offering a significant new treatment option for a highly lethal cancer.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.